Healthy Vaccinee Bias and MenB-FHbp Vaccine Effectiveness Against Gonorrhea.
Journal
Sexually transmitted diseases
ISSN: 1537-4521
Titre abrégé: Sex Transm Dis
Pays: United States
ID NLM: 7705941
Informations de publication
Date de publication:
01 06 2023
01 06 2023
Historique:
pmc-release:
01
06
2024
medline:
15
5
2023
pubmed:
3
3
2023
entrez:
2
3
2023
Statut:
ppublish
Résumé
Observational studies demonstrated 30% to 40% effectiveness of outer-membrane vesicle (OMV) meningococcal serogroup B vaccines against gonorrhea. To explore whether healthy vaccinee bias influenced such findings, we examined the effectiveness of MenB-FHbp, a non-OMV vaccine that is not protective against gonorrhea. MenB-FHbp was ineffective against gonorrhea. Healthy vaccinee bias likely did not confound earlier studies of OMV vaccines.
Identifiants
pubmed: 36863060
doi: 10.1097/OLQ.0000000000001793
pii: 00007435-202306000-00016
pmc: PMC10175191
mid: NIHMS1877330
doi:
Substances chimiques
Meningococcal Vaccines
0
Antigens, Bacterial
0
Types de publication
Journal Article
Research Support, N.I.H., Intramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
e8-e10Subventions
Organisme : Intramural CDC HHS
ID : CC999999
Pays : United States
Informations de copyright
Copyright © 2023 American Sexually Transmitted Diseases Association. All rights reserved.
Déclaration de conflit d'intérêts
Conflict of Interest and Sources of Funding: None declared.
Références
Unemo M, Shafer WM. Antimicrobial resistance in Neisseria gonorrhoeae in the 21st century: Past, evolution, and future. Clin Microbiol Rev 2014; 27:587–613.
Kirkcaldy RD, Kidd S, Weinstock HS, et al. Trends in antimicrobial resistance in Neisseria gonorrhoeae in the USA: The Gonococcal Isolate Surveillance Project (GISP), January 2006–June 2012. Sex Transm Infect 2013; 89:iv5–iv10.
Abara WE, Jerse AE, Hariri S, et al. Planning for a gonococcal vaccine: A narrative review of vaccine development and public health implications. Sex Transm Dis 2021; 48:453–457.
Pérez O, Del Campo J, Cuello M, et al. Mucosal approaches in Neisseria vaccinology. VacciMonitor 2009; 18:53–55.
Whelan J, Kløvstad H, Haugen IL, et al. Ecologic study of meningococcal B vaccine and Neisseria gonorrhoeae infection, Norway. Emerg Infect Dis 2016; 22:1137–1139.
Longtin J, Dion R, Simard M, et al. Possible impact of wide-scale vaccination against serogroup B Neisseria meningitidis on gonorrhea incidence rates in one region of Quebec, Canada. Open Forum Infect Dis 2017; s734–s735.
Petousis-Harris H, Paynter J, Morgan J, et al. Effectiveness of a group B outer membrane vesicle meningococcal vaccine against gonorrhoea in New Zealand: A retrospective case-control study. Lancet 2017; 390:1603–1610.
Abara WE, Bernstein KT, Lewis FMT, et al. Effectiveness of a serogroup B outer membrane vesicle meningococcal vaccine against gonorrhoea: A retrospective observational study. Lancet Infect Dis 2022; 22:1021–1029.
Wang B, Giles L, Andraweera P, et al. Effectiveness and impact of the 4CMenB vaccine against invasive serogroup B meningococcal disease and gonorrhoea in an infant, child, and adolescent programme: An observational cohort and case-control study. Lancet Infect Dis 2022; 22:1011–1020.
Semchenko EA, Tan A, Borrow R, et al. The serogroup B meningococcal vaccine Bexsero elicits antibodies to Neisseria gonorrhoeae . Clin Infect Dis 2019; 69:1101–1111.
Mbaeyi SA, Bozio CH, Duffy J, et al. Meningococcal vaccination: Recommendations of the advisory committee on immunization practices, United States, 2020. MMWR Recomm Rep 2020; 69:1–41.
Food and Drug Administration. Bexsero 2020. Available at: https://www.fda.gov/media/90996/download . Accessed September 1, 2022.
Semchenko EA, Day CJ, Seib KL. The Neisseria gonorrhoeae vaccine candidate NHBA elicits antibodies that are bactericidal, opsonophagocytic and that reduce gonococcal adherence to epithelial cells. Vaccine 2020; 8:219.
Leduc I, Connolly KL, Begum A, et al. The serogroup B meningococcal outer membrane vesicle–based vaccine 4CMenB induces cross-species protection against Neisseria gonorrhoeae . PLoS Pathog 2020; 16:e1008602.
Mahmud SM, Righolt CH. Pitfalls of the healthy vaccinee effect. Lancet 2018; 391:123.
Shrank WH, Patrick AR, Brookhart MA. Healthy user and related biases in observational studies of preventive interventions: A primer for physicians. J Gen Intern Med 2011; 26:546–550.
Food and Drug Administration. Trumenba 2018. Available at: https://www.fda.gov/media/89936/download . Accessed September 1, 2022.
Marjuki H, Topaz N, Joseph SJ, et al. Genetic similarity of gonococcal homologs to meningococcal outer membrane proteins of serogroup B vaccine. mBio 2019; 10:e01668–e01619.
Jongerius I, Lavender H, Tan L, et al. Distinct binding and immunogenic properties of the gonococcal homologue of meningococcal factor H binding protein. PLoS Pathog 2013; 9:e1003528.
Drazan D, Czajka H, Maguire JD, et al. A phase 3 study to assess the immunogenicity, safety, and tolerability of MenB-FHbp administered as a 2-dose schedule in adolescents and young adults. Vaccine 2022; 40:351–358.
National Institutes of Health. Safety and efficacy study of meningococcal group B vaccine rMenB+OMV NZ (Bexsero) to prevent gonococcal infection. Available at: https://clinicaltrials.gov/ct2/show/NCT04350138 . Accessed September 1, 2022.
National Institutes of Health. Efficacy study of 4CMenB (Bexsero®) to prevent gonorrhea infection in gay and bisexual men (GoGoVax). Available at: https://clinicaltrials.gov/ct2/show/NCT04415424 . Accessed September 1, 2022.
National Institutes of Health. Study to assess gonorrhea immune responses induced by a N. meningitides vaccine (4CMenB). Available at: https://clinicaltrials.gov/ct2/show/NCT04094883 . Accessed September 1, 2022.